Strategic Brief · Privileged & Confidential
Strategic Brief · Privileged & Confidential
Galen Growth × Altaris / LS&H
Cortellis answers the molecule's R&D questions. DRG answers its commercialization questions. HealthTech Alpha answers what your customers ask next — what the healthcare-technology ecosystem is doing around the molecule. This is not a better Cortellis. It is the layer Cortellis was never built to be.
You are standing up a scaled, independent life-sciences intelligence platform. The roadmap you write between signing and close decides what that platform is on day one — a separation story, or a growth story. This page is about one decision on that roadmap.
The market priced LS&H the way it prices any scaled asset without a growth story. You bought the platform; what re-rates it is growth and workflow ownership. HealthTech Alpha is the growth layer that arrives complete — a new sellable coverage module, an entity-resolved crosswalk into Cortellis and DRG, and the evidence-graded data foundation the platform's AI roadmap requires.
LS&H owns the molecule's lifecycle. It does not own the innovation layer around it — the 17,000+ ventures and products that pharma, medtech, payers, investors and providers now track as seriously as pipelines.
Nothing in the module competes with a Cortellis or DRG product line. It extends the platform into the layer its customers already ask about — the adjacency, already curated, already trusted.
Put the engine inside the platform you just bought; don't bolt a layer onto the side of it.
HealthTech Alpha's ontology joins its companies, products, partnerships, trials and regulatory records to Cortellis pipeline entities and DRG market-access data — one resolved graph from molecule to innovation ecosystem.
Healthcare-technology innovation intelligence ships as a module in the commercial engine you already run — an upsell to ~2,500 accounts, plus buyer types the platform doesn't yet serve at scale: investors, payers, providers, consultancies.
AI-enabled intelligence workflows need curated, auditable domain data. Evidence grading is precisely that infrastructure — a workflow and a customer base built over eleven years, not a feature to ship.
Illustrative, deliberately conservative, and yours to replace. Three levers decide what the module is worth to the platform.
One therapeutic area. HealthTech Alpha entities crosswalked to pipeline and market-access views — and five questions answered live that the platform cannot answer today.
Which digital-therapeutics products in type-2 diabetes have peer-reviewed adherence evidence — and which top-20 pharma do they partner with?
Which CGM-adjacent ventures hold FDA clearance plus an active pharma co-development?
Which technologies will shape market access for the next GLP-1 generation?
The gap is the thesis. We show it on a single screen, on your accounts' own questions.
A build cannot close this gap on a carve-out timeline — and the window to shape the day-one roadmap is between signing and close.
Per Galen Growth's published Value Defender analysis — across proprietary data, evidence-linked ontology, expert validation and global commercial trust — with execution risk, not cost, as the central concern.
Every carve-out launches with a separation story. A signed growth module, timed to close, lets the platform launch with a growth story instead — to customers, to talent, and eventually to the exit market.
Simulations Plus combining with Chemical Computing Group is Altaris assembling a platform on the biosimulation leg. HealthTech Alpha into LS&H is the same move on the intelligence leg.
Galen Growth has been deliberate about where eleven years of curation lands. The right home is the platform where healthcare-technology intelligence becomes core infrastructure for the industry — not a feature inside someone else's product. A focused, independent LS&H, resourced by a healthcare-exclusive owner, is that home. The principals seek an outright sale, are flexible on structure and timing — including alignment to your close calendar — and intend to lead the layer inside the platform.
The strategic process is being run by Kane & Company, retained sell-side advisor to Galen Growth. Principal participation is available once a mutual NDA is in place.
Thirty minutes, before close, where the Galen Growth principals show the combined graph on one therapeutic area. Tuesday at 1:00 PM ET or Thursday at 10:00 AM ET — or a time convenient to you.
Michael · Managing Partner · Kane & Company · Commerce@kaneco.com · Retained sell-side advisor to Galen Growth